Since 2015, Inserm has been developing programs that aim to accelerate technology research and provide its research teams with the most innovative technologies.
Scientific research is increasingly dependent on access to cutting-edge technology. To provide itself with the capacity for innovation and technological development, and to translate technology into its laboratories, Inserm has developed its technology research accelerators (ARTs).
These structures aim not only to develop innovative technologies, but also to make them available to the research teams who may benefit from them. An important component of their work is providing research staff with training in the use of technological innovations.
Biomedical Ultrasound ART
This first ART, created in 2016, is dedicated to research and use of medical ultrasound, particularly in the diagnosis and treatment of cancer, and in neurological and cardiovascular disease.
This new theme-based structure brings together multiple skills within the same unit in order to develop innovative technologies and provide them to other Inserm laboratories.
The Biomedical Ultrasound ART is located within the Institut de la Vision in Paris. Part of the Langevin Institute, it has been developed in partnership with the CNRS and the ESPCI Paris, a recruiting ground for the top engineers and researchers of the future.
This ART aims to support the integration of 3D cell printing within Inserm laboratories. Its objective is to accelerate the development of cellular models for fundamental research, organoids for research in pharmacology, and the uses of bioprinting for research in regenerative medicine. Notably it provides training and production services to Inserm laboratories.
Created in 2017, this ART was developed in partnership with the Université de Bordeaux (Inserm unit 1026, BioTis).
For more information:
Read the press release: BioPrint: Inserm Launches its Second Accelerator of Technological Research (October 12, 2017)
Read the press pack: Laser bioprinting in Bordeaux: an innovative approach (July 4, 2014)
Genomic Therapy ART
This third ART brings technological, preclinical and pharmaceutical skills for the development of innovation in gene therapy from Inserm laboratories. It focuses in particular on so-called genomic therapy approaches, which consist in stably modifying the genome of target somatic cells in order to obtain a lasting effect, including in tissues undergoing strong division. This approach, which has already shown its worth, makes it possible to combine gene and cell therapies. For example, it uses lentiviral vectors or CRISPR genome editing tools.
Created on January 1, 2018, the Genomic Therapy ART is directed by Anne Galy. It will focus on immunology or hematology applications of genomic therapy.
ARTs Under Consideration
- Artificial Intelligence in the Clinic